Amphista Clears FDA Hurdle for AML Drug, Sets Clinical Trial
Event summary
- FDA cleared Amphista's IND application for AMX-883, a BRD9 degrader for AML.
- Phase 1 monotherapy trial to begin in H2 2026 for relapsed/refractory AML and high-risk MDS.
- AMX-883 is orally bioavailable and acts independently of karyotype status.
- Company plans to explore AMX-883 combinations with venetoclax and azacitidine.
The big picture
Amphista's FDA clearance marks its transition to a clinical-stage company, addressing a critical unmet need in AML where resistance to standard treatments like venetoclax remains a major challenge. The company's proprietary Targeted Glue™ technology differentiates it in the competitive landscape of targeted protein degradation therapies. Success in this trial could validate Amphista's approach and attract further investment in its pipeline.
What we're watching
- Clinical Efficacy
- Whether AMX-883 can demonstrate meaningful efficacy in AML patients, particularly those resistant to current treatments.
- Combination Strategy
- The pace at which Amphista advances AMX-883 into combination therapies with venetoclax and azacitidine.
- Market Differentiation
- How AMX-883's karyotype-independent mechanism positions it against emerging AML therapies.
Related topics